Adagene Inc. (ADAG) Key Metrics

NASDAQ: ADAGValuation, returns, debt and efficiency ratios over 8 years.

ADAG valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$138.3M
Enterprise value
$76.3M
P/E (TTM)
—
Forward P/E
—
PEG ratio
—
Price / sales
14.9
10-yr median 9.3
Price / book
2.2
10-yr median 1.4
EV / EBITDA
1.1
Dividend yield
—
Beta
0.54

ADAG key metrics, 2018–2025

Fiscal year ended December 31, 2025 · U.S. dollars

ADAG valuation Price multiples at each fiscal year-end price.

Price / sales−98.7%
9.3
2025 · hover or tap a bar for each year
2021: 25.42022: 4.9 (−80.5%)2023: 3.7 (−24.4%)2024: 694.6 (+18,497.7%)2025: 9.3 (−98.7%)
20182025
Price / book+42.3%
2.0
2025 · hover or tap a bar for each year
2021: 1.72022: 0.6 (−66.5%)2023: 1.0 (+73.5%)2024: 1.4 (+48.0%)2025: 2.0 (+42.3%)
20182025
Free cash flow yield+19.5 pts
−22.0%
2025 · hover or tap a bar for each year
2021: −17.8%2022: −107.4% (−89.6 pts)2023: −42.2% (+65.2 pts)2024: −41.5% (+0.7 pts)2025: −22.0% (+19.5 pts)
20182025

ADAG valuation history

Fiscal year-endToday8-year median

ADAG returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

ADAG debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

ADAG cash returned to shareholders

DividendsBuybacksFree cash flow

ADAG price vs earnings per share

Share price at year-endEPS (right axis)

ADAG key metrics

2018–2025
Adagene Inc. key metrics by fiscal year
20252024202320222021202020192018
Valuation
Market capitalization$71.4M$71.7M$67.6M$45.9M$258.3M———
Enterprise value$3.1M$5.0M−$20.0M−$69.9M$91.4M———
Price / sales9.3694.63.74.925.4———
Price / book2.01.41.00.61.7———
EV / sales0.448.3-1.1-7.59.0———
Earnings yield−24.7%−46.6%−28.0%−174.2%−28.3%———
Free cash flow yield−22.0%−41.5%−42.2%−107.4%−17.8%———
Dividend yield———0.7%1.8%———
Shareholder yield (dividends + buybacks)—0.0%0.0%9.4%2.7%———
Share price at fiscal year-end$1.89$1.99$1.93$1.32$8.07———
Per share
Revenue per share$0.20$0.00$0.52$0.27$0.32$0.02$0.01—
Earnings per share−$0.47−$0.93−$0.54−$2.31−$2.29−$0.59−$0.49—
Operating cash flow per share−$0.41−$0.82−$0.81−$1.40−$1.36−$1.02−$0.51—
Free cash flow per share−$0.42−$0.83−$0.81−$1.42−$1.43−$1.05−$0.52—
Cash per share$1.97$2.36$3.14$4.15$5.45$2.68$2.85—
Book value per share$0.94$1.40$2.01$2.40$4.89−$3.19−$1.61—
Tangible book value per share$0.94$1.40$2.01$2.40$4.89−$3.19−$1.61—
Dividends per share———$0.01$0.14———
Capex per share$0.00$0.00$0.00$0.02$0.08$0.03$0.00—
Debt per share$0.17$0.51$0.64$0.81$0.23$0.28$0.07—
Shares outstanding37.8M36.0M35.0M34.6M32.0M28.1M35.3M—
Change in shares outstanding+4.8%+2.8%+1.1%+8.2%+14.1%−20.6%——
Returns & profitability
Return on equity (ROE)−41.0%−55.2%−24.7%−66.7%−217.9%———
Return on assets (ROA)−21.0%−32.6%−14.1%−46.8%−53.5%−17.3%−21.6%−27.0%
Return on tangible assets−22.5%−37.4%−16.4%−52.5%−38.6%−19.5%−16.3%−27.0%
Free cash flow margin−204.3%—−157.6%−530.6%−451.3%——−978.0%
Financial health
Total debt$6.3M$18.5M$22.3M$28.0M$7.5M$8.0M$2.6M$2.3M
Cash & short-term investments$74.5M$85.2M$109.9M$143.8M$174.4M$75.2M$100.5M$49.1M
Net debt−$68.3M−$66.7M−$87.6M−$115.8M−$166.9M−$67.2M−$98.0M−$46.7M
Debt / equity0.180.370.320.340.05———
Debt / assets0.080.210.190.180.040.090.020.04
Current ratio3.072.303.612.716.244.9014.475.01
Quick ratio3.072.303.612.716.244.9014.475.01
Interest coverage-46.3-42.2-21.4-121.0-198.9-94.8-138.8-190.3
Working capital$52.2M$49.6M$82.0M$94.2M$156.1M$63.0M$96.7M$41.5M
Invested capital−$32.9M−$16.2M−$17.1M−$32.7M−$10.3M−$156.6M−$155.0M−$87.8M
Tangible asset value$35.3M$50.5M$70.6M$83.1M$156.6M−$89.4M−$57.0M−$41.0M
Net current asset value$34.5M$49.0M$68.3M$80.0M$153.0M−$94.6M−$59.0M−$43.6M
Graham net-net per share$0.84$1.29$1.85$2.16$4.59−$3.51−$1.72—
Capital allocation
Dividends paid———$322,827$4.6M———
Share buybacks (net)—$0$0$4.0M$2.4M$0——
Capex / revenue0.2%32.5%0.5%7.4%24.7%194.8%31.6%34.1%
Capex / depreciation0.030.040.070.482.231.090.190.57
Stock-based compensation / revenue48.8%4,757.2%40.1%113.2%183.6%2,110.3%127.4%8.4%
R&D / revenue287.2%27,887.9%202.3%875.3%669.3%3,377.4%3,377.4%1,064.1%
SG&A / revenue92.2%7,047.5%47.9%127.8%141.9%716.2%716.2%183.0%
Efficiency
Days sales outstanding0.6407.38.5159.6137.0864.21,357.6345.4
Days payables outstanding2,232.21,445.3——————
Cash conversion cycle (days)-2,231.6-1,038.0——————
Receivables turnover597.930.9043.052.292.660.420.271.06
Payables turnover0.160.250.000.000.000.000.000.00
Inventory turnover————0.00—0.00—
Asset turnover0.090.000.140.050.070.010.010.03
Average receivables$12,829$115,168$420,730$4.1M$3.8M$1.1M$1.8M$1.4M
Average payables$3.6M$3.7M$3.4M$3.5M$2.6M$1.3M$635,846$558,977
Average inventory————$1—$1—
Intangibles / total assets0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Computed from ADAG's annual financial statements (latest annual report filed April 1, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

ADAG valuation and financial ratios

Adagene earned a return on equity of −41.0% in fiscal 2025. It ended the year with $6.3 million of debt and $74.5 million in cash and short-term investments, a net cash position of $68.3 million.

See the ADAG income statement, the ADAG chart for price history, or the ADAG stock overview for the latest quote and news.

ADAG key metrics FAQ

What is Adagene's return on equity?

Adagene's return on equity (ROE) was −41.0% in fiscal 2025: net income of -$17.6 million on average shareholders' equity of $42.9 million.

How much debt does Adagene have?

Adagene had total debt of $6.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.18 and more cash than debt.

What is Adagene's free cash flow yield?

Adagene generated -$15.7 million of free cash flow in fiscal 2025, a free cash flow yield of −22.0% on its market value at year-end ($71.4 million).

What is Adagene's current ratio?

Adagene's current ratio was 3.07 at the end of fiscal 2025: current assets were 3.07 times current liabilities.

Biotechnology key metrics